![Edward Berg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Edward Berg
General Counsel bei
VAXART, INC.
Vermögen: 456 998 $ am 30.06.2026
Profil
Edward B. Berg is General Counsel & Senior Vice President at Vaxart, Inc. since 2022.
Former roles include Vice President & Deputy General Counsel at BioMarin Pharmaceutical, Inc. from 2018 to 2022; Deputy General Counsel-Pharmaceutical Operations at Sanofi-Aventis U.S.
LLC from 2008 to 2018; Vice President at Sandoz, Inc. from 2016 to 2018; Vice President-Legal at Novartis AG from 2016 to 2018; Senior Corporate Counsel-Research & Development at Bristol Myers Squibb Co. from 2006 to 2008; and Senior Attorney & Associate Counsel at Merck & Co., Inc. from 1993 to 2001.
Education includes undergraduate studies at the University of Washington and graduate studies at The University of Pennsylvania Law School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
VAXART, INC. 0,31 % | 24.03.2026 | 755.368 ( 0,31 % ) | 456 998 $ | 30.06.2026 |
Aktive Positionen von Edward Berg
| Unternehmen | Position | Beginn |
|---|---|---|
| VAXART, INC. | General Counsel | 14.02.2022 |
Ehemalige bekannte Positionen von Edward Berg
| Unternehmen | Position | Ende |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.02.2022 |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Corporate Officer/Principal | 01.06.2018 |
| NOVARTIS AG | General Counsel | 01.06.2018 |
Sanofi-Aventis U.S. LLC
 Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Develops medicines, vaccines and provides specialized healthcare & clinical trail services | Corporate Officer/Principal | 01.06.2018 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01.08.2008 |
Ausbildung von Edward Berg
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
79
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
BioMarin Pharmaceutical, Inc.
 BioMarin Pharmaceutical, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes innovative pharmaceuticals for serious diseases & medical conditions | Health Technology |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sanofi-Aventis U.S. LLC
Sanofi-Aventis U.S. LLC Pharmaceuticals: MajorHealth Technology Develops medicines, vaccines and provides specialized healthcare & clinical trail services | Health Technology |
The University of Pennsylvania Law School
 The University of Pennsylvania Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vaxart, Inc.
 Vaxart, Inc. BiotechnologyHealth Technology Develops vaccines | Health Technology |
